Request Offer


  • Novapep is an early stage biotech company which has secured the exclusive world-wide license for the novel patented peptide TR47 from the Scripps Research Institute.

  • Novapep is researching the potential of TR47 in vasculitis, nephritis, atopic dermatitis and autoimmune diseases, based on strong supporting scientific data.

  • Seed funding has been raised and the University of Sydney is an investor.